Publication | Closed Access

Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: Insights from the Flolan International Randomized Survival Trial (FIRST)

Heart FailureCardiovascular DiseasePatient SafetyContinuous Intravenous DobutaminePharmacotherapyCardiac CareAcute Myocardial InfarctionCardiovascular ToxicityMedicineAdvanced Heart FailureCardiologyAnesthesiologyMyocardial Infarction